- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.08. | H.C. Wainwright reiterates Buy rating on Gain Therapeutics stock at $8 price target | 2 | Investing.com | ||
| 25.08. | BTIG lowers Gain Therapeutics stock price target to $9 on biomarker data timing | 2 | Investing.com | ||
| 12.08. | Gain Therapeutics, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 12.08. | Gain Therapeutics GAAP EPS of -$0.19 misses by $0.02 | 1 | Seeking Alpha | ||
| 17.07. | Gain Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.07. | Gain Therapeutics, Inc.: Gain Therapeutics Announces Pricing of $7.0 Million Public Offering | 2 | GlobeNewswire (USA) | ||
| 15.07. | Gain Therapeutics stock falls after announcing public offering | 2 | Investing.com | ||
| GAIN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 15.07. | Gain Therapeutics announces proposed public offering | 1 | Seeking Alpha | ||
| 15.07. | Gain Therapeutics-Aktie fällt nach Ankündigung einer Kapitalerhöhung | 3 | Investing.com Deutsch | ||
| 15.07. | Gain Therapeutics, Inc.: Gain Therapeutics Announces Proposed Public Offering | 1 | GlobeNewswire (USA) | ||
| 03.07. | Gain Therapeutics stock advances as Phase 1b trial enrollment exceeds expectations | 1 | Investing.com | ||
| 30.06. | Gain Therapeutics, Inc.: Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson's Disease With or Without a GBA1 Mutation | 86 | GlobeNewswire (Europe) | As of June 30th, 16 participants have enrolled in the Phase 1b, ahead of the original goal of at least 15 total participants by 3Q 2025 Analysis of 90-day biomarker activity from cerebrospinal fluid... ► Artikel lesen | |
| 24.06. | Gain Therapeutics erhöht genehmigte Stammaktien nach Aktionärsabstimmung auf 100 Millionen | 1 | Investing.com Deutsch | ||
| 24.06. | Gain Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.05. | Gain Therapeutics, Inc.: Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting | 2 | GlobeNewswire (USA) | ||
| 28.05. | Gain Therapeutics announces $100M mixed shelf offering | 1 | Seeking Alpha | ||
| 14.05. | Gain Therapeutics, Inc.: Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update | 211 | GlobeNewswire (Europe) | BETHESDA, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the... ► Artikel lesen | |
| 12.05. | Gain Therapeutics, Inc.: Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders | 2 | GlobeNewswire (USA) | ||
| 30.04. | Gain Therapeutics, Inc.: Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders | 2 | GlobeNewswire (USA) | ||
| 10.04. | Gain Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MINERALYS THERAPEUTICS | 28,860 | 0,00 % | Mineralys Therapeutics prices upsized $250M stock offering | ||
| AVIDITY BIOSCIENCES | 47,230 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 40,690 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update | Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera's target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,200 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| ARCELLX | 69,75 | 0,00 % | Arcellx, Inc. (ACLX) Reports 97% Response Rate in CAR-T Trial | ||
| TARSUS PHARMACEUTICALS | 58,59 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 23,840 | 0,00 % | H.C. Wainwright hebt Kursziel für Summit Therapeutics auf 50 US-Dollar an | ||
| TREVI THERAPEUTICS | 7,270 | 0,00 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates | Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF
Closed $115 million underwritten... ► Artikel lesen | |
| NUVALENT | 76,90 | 0,00 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 44,940 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines to Participate in Upcoming Fireside Chat | ||
| UPSTREAM BIO | 20,260 | 0,00 % | Upstream Bio, Inc. - 8-K, Current Report | ||
| RECURSION PHARMACEUTICALS | 4,660 | 0,00 % | If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today | ||
| CG ONCOLOGY | 27,460 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates | - Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec at the American Urological Association Annual Meeting - ... ► Artikel lesen | |
| BEAM THERAPEUTICS | 16,310 | 0,00 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| DYNE THERAPEUTICS | 13,500 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) | - Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug.... ► Artikel lesen |
GAIN THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,910 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GAIN THERAPEUTICS INC finden Sie auf Wallstreet Online.